Unusual binding mode of an HIV-1 protease inhibitor explains its potency against multi-drug-resistant virus strains

Journal of Molecular Biology

Volumn 324, Issue 4, 2002, Pages 739-754

  Weber, Jan ^a,f   Mesters, Jeroen R ^b   Lepšík, Martin ^a   Prejdová, Jana ^a   Švec, Martin ^a   Šponarová, Jana ^a   Mlčochová, Petra ^a   Skalická, Kristina ^a   Stříšovský, Kvido ^a   Uhlíková, Táňa ^a   Souček, Milan ^a   Machala, Ladislav ^c   Staňková, Marie ^c   Vondrášek, Jiří ^a   Klimkait, Thomas ^d   Kraeusslich, Hans Georg ^e   Hilgenfeld, Rolf ^b   Konvalinka, Jan ^a  

^a INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^b FRITZ LIPMANN INSTITUTE   (Germany)

^c UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

^d UNIVERSITY OF BASEL   (Switzerland)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f LERNER RESEARCH INSTITUTE   (United States)

Author keywords

HIV drug resistance; HIV protease inhibitor; Rational drug design; X ray structure

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; QF 34; RITONAVIR; SAQUINAVIR; UNCLASSIFIED DRUG; VIRUS ENZYME;

ARTICLE; CHEMICAL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CZECH REPUBLIC; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; ENZYME KINETICS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KINETICS; MALE; MOLECULAR MODEL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; STRUCTURE ANALYSIS; VIRUS LOAD; VIRUS MUTATION; VIRUS STRAIN; X RAY CRYSTALLOGRAPHY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0036922924     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2836(02)01139-7     Document Type: Article

References (55)

1. Coffin, J. M. (1995). HIV population dynamics in vivo: Implications for genetic variations, pathogenesis and therapy. Science, 267, 483-489.
2. Erickson, J. W. & Burt, S. K. (1996). Structural mechanisms of HIV drug resistance Annu. Rev. Pharmacol. Toxicol. 36, 545-571.
3. Doyon, L., Croteau, G., Thibeault, D., Poulin, F., Pilote, L. & Lamarre, D. (1996). Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 70, 3763-3769.
4. Zhang, Y. M., Imamichi, H., Imamichi, T., Lane, H. C., Falloon, J., Vasudevachari, M. B. & Salzman, N. P. (1997). Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol. 71, 6662-6670.
5. Schechter, I. & Berger, A. (1967). On the size of the active site in proteases. Biochem. Biophys. Res. Commun. 27, 157-162.
6. Condra, J. H., Schleif, W. A., Blahy, O. M., Gabryelski, L. J., Graham, D. J., Quintero, J. C. et al. (1995). In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature, 374, 569-571.
7. Molla, A., Korneyeva, M., Gao, Q., Vasavanonda, S., Schipper, P. J., Mo, H.-M. et al. (1996). Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med. 2, 760-766.
8. Boden, D. & Markowitz, M. (1998). Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob. Agents Chemother. 42, 2775-2783.
9. Ridky, T. & Leis, J. (1995). Development of drug resistance to HIV-1 protease inhibitors. J. Biol. Chem. 270, 29621-29623.
10. Wlodawer, A. & Vondrášek, J. (1998). Inhibitors of HIV-1 protease: A major succes of structure-assisted drug design. Annu. Rev. Biophys. Biomol. Struct. 27, 249-284.
11. Wlodawer, A. (2002). Rational approach to AIDS drug design through structural biology. Annu. Rev. Med. 53, 595-614.
12. Olsen, D. B., Stahlhut, M. W., Rutkowski, C. A., Schock, H. B., vanOlden, A. L. & Kuo, L. C. (1999). Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors. J. Biol. Chem. 274, 23699-23701.
13. Markowitz, M., Conant, M., Hurley, A., Schluger, R., Duran, M., Peterkin, J. et al. (1998). A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J. Infect. Dis. 177, 1533-1540.
14. Rose, R. E., Gong, Y. F., Greytok, J. A., Bechtold, C. M., Terry, B. J., Robinson, B. S. et al. (1996). Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc. Natl. Acad. Sci. USA, 93, 1648-1653.
15. Jacobsen, H., Hanggi, M., Ott, M., Duncan, I. B., Owen, S., Andreoni, M. et al. (1996). In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: Mutations, kinetics, frequencies. J. Infect. Dis. 173, 1379-1387.
16. Jacobsen, H., Yasargil, K., Winslow, D. L., Craig, J. C., Kroehn, A., Duncan, I. B. & Mous, J. (1995). Characterization of human immunodeficiency virus type 1 mutant with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology, 206, 527-534.
17. Vasudevachari, M. B., Zhang, Y. M., Imamichi, H., Imamichi, T., Falloon, J. & Salzman, N. P. (1996). Emergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid screening procedure for their detection. Antimicrob. Agents Chemother. 40, 2535-2541.
18. Patick, A. K., Duran, M., Cao, Y., Shugarts, D., Keller, M. R., Mazabel, E. et al. (1998). Genotypic analysis of HIV-1 variants isolated from patients treated with the protease inhibitor, nelfinavir. Antimicrob. Agents Chemother. 42, 2637-2644.
19. Markland, W., Rao, B. G., Parsons, J. D., Black, J., Zuchowski, L., Tisdale, M. & Tung, R. (2000). Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir. J. Virol. 74, 7636-7641.
20. Chen, Z., Li, Y., Chen, E., Hall, D. L., Darke, P. L., Culberson, C. et al. (1994). Crystal structure at 1.9 Å resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bio-available inhibitor of the HIV proteases. J. Biol. Chem. 269, 26344-26348.
21. Baldwin, E. T., Bhat, T. N., Liu, B., Pattabiraman, N. & Erickson, J. W. (1995). Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase. Nature Struct. Biol. 2, 244-249.
22. Ala, P. J., Huston, E. E., Klabe, R. M., McCabe, D. D., Duke, J. L., Rizzo, C. J. et al. (1997). Molecular basis of HIV-1 protease drug resistance: Structural analysis of mutant proteases complexed with cyclic urea inhibitors. Biochemistry, 36, 1573-1580.
23. Hong, L., Zhang, X. C., Hartsuck, J. A. & Tang, J. (2000). Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: Insights into the mechanisms of drug resistance. Protein Sci. 9, 1898-1904.
24. Munshi, S., Chen, Z., Yan, Y., Li, Y., Olsen, D. B., Shock, H. B. et al. (2000). An alternative binding site for the P1-P3 group of a class of potent HIV protease inhibitors as a result of concerted structural change in the 80 S loop of the protease. Acta Crystallog. Sect. D, 56, 381-388.
25. Mahalingam, B., Louis, J. M., Reed, C. C., Adomat, J. M., Krouse, J., Wang, Y. F. et al. (1999). Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. Eur. J. Biochem. 263, 238-245.
26. Mahalingam, B., Louis, J. M., Hung, J., Harrison, R. W. & Weber, I. T. (2001). Structural implications of drug-resistant mutants of HIV-1 protease: High-resolution crystal structures of the mutant protease/substrate analogue complexes. Proteins: Struct. Funct. Genet. 43, 455-464.
27. Yoshimura, K., Kato, R., Yusa, K., Kavlick, M. F., Maroun, V., Nguyen, A. et al. (1999). JE-2147: A dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. Proc. Natl. Acad. Sci. USA, 96, 8675-8680.
28. Yoshimura, K., Kato, R., Kavlick, M. F., Nguyen, A., Maroun, V., Maeda, K. et al. (2002). A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site. J. Virol. 76, 1349-1358.
29. Weber, J., Majer, P., Litera, J., Urban, J., Souček, M., Vondrášek, J. et al. (1997). Potency comparison of peptidomimetic inhibitors against HIV-1 and HIV-2-proteinases: Design of equipotent lead compounds. Arch. Biochem. Biophys. 341, 62-69.
30. Konvalinka, J., Litera, J., Weber, J., Vondrášek, J., Hradílek, M., Souček, M. et al. (1997). Configurations of diastereomeric hydroxyethylene isosteres strongly afect biological activities of a series of specific inhibitors of human-immunodeficiency-virus proteinase. Eur. J. Biochem. 250, 559-566.
31. Kervinen, J., Lubkowski, J., Zdanov, A., Bhatt, D., Dunn, B. M., Hui, K. Y. et al. (1998). Toward a universal inhibitor of retroviral proteases: Comparative analysis of the interactions of LP-130 complexed with proteases from HIV-I, FIV, and EIAV. Protein Sci. 7, 2314-2323.
32. Wilson, S. I., Phylip, L. H., Mills, J. S., Gulnik, S. V., Erickson, J. W., Dunn, B. M. & Kay, J. (1997). Escape mutants of HIV-1 proteinase: Enzymic efficiency and susceptibility to inhibition. Biochim. Biophys. Acta, 1339, 113-125.
33. Rinnová, M., Hradilek, M., Bařinka, C., Weber, J., Souček, M., Vondrášek, J. et al. (2000). A picomolar inhibitor of resistant strains of HIV PR identified by a combinatorial approach. Arch. Biochem. Biophys. 382, 22-30.
34. Stříšovský, K., Tessmer, U., Langner, J., Konvalinka, J. & Krausslich, H.-G. (2000). Systematic mutational analysis of the active-site threonine of HIV-1 proteinase: Re-thinking the fireman's grip hypothesis. Protein Sci. 9, 1631-1641.
35. Lazdins, J. K., Mestan, J., Goutte, G., Walker, M. R., Bold, G., Capraro, H. G. & Klimkait, T. (1997). In vitro effect of alpha(1)-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: A comparative study with other relevant HIV protease inhibitors. J. Infect. Dis. 175, 1063-1070.
36. Richards, A. D., Phylip, L. H., Farmerie, W. G., Scarborough, P. E., Alvarez, A., Dunn, B. M. et al. (1990). Sensitive, soluble chromogenic substrates for HIV-1 proteinase. J. Biol. Chem. 265, 7733-7736.
37. Konvalinka, J., Literst, M. A., Welker, R., Kottler, H., Rippman, F., Heuser, A.-M. & Krausslich, H.-G. (1995). An active site mutation in the human immunodeficiency virus type-1 proteinase (PR) causes reduced PR activity and loss of PR mediated cytotoxicity without apparent effect on virus maturation and infectivity. J. Virol. 69, 7180-7186.
38. Klabe, R. M., Bacheler, L. T., Ala, P. J., Erickson-Viitanen, S. & Meek, J. L. (1998). Resistance to HIV protease inhibitors: A comparison of enzyme inhibition and antiviral potency. Biochemistry, 37, 8735-8742.
39. Gulnik, S. V., Suvorov, L. I., Liu, B., Yu, B., Anderson, B., Mitsuya, H. & Erickson, J. W. (1995). Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry, 34, 9282-9287.
40. Krohn, A., Redshaw, S., Ritchie, J. C., Graves, B. J. & Hatada, M. H. (1991). Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. J. Med. Chem. 34, 3340-3342.
41. Laskowski, R. A. (1995). Surfnet: A program for visualizing molecular surfaces, cavities and intermolecular interactions. J. Mol. Graph. 13, 323-330.
42. Williams, J. W. & Morrison, J. F. (1979). The kinetics of reversible tight-binding inhibition. Methods Enzymol. 63, 437-467.
43. Riboldi-Tunnicliffe, A. & Hilgenfeld, R. (1999). Cryocrystallography with oil - An old idea revived. J. Appl. Crystallog. 32, 1003-1005.
44. Otwinowski, Z. & Minor, W. (1997). Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326.
45. Fitzgerald, P. M. D., McKeever, B. M., Van-Middlesworth, J. F., Springer, J. P., Heimbach, J. C., Leu, C.-T. et al. (1990). Crystallographic analysis of a complex between human-immunodeficiency-virus type-1 protease and acetyl-pepstatin at 2.0 Å resolution. J. Biol. Chem. 265, 14209-14219.
46. Vagin, A. & Teplyakov, A. (1997). MOLREP, an automated program for molecular replacement. J. Appl. Crystallog. 30, 1022-1025.
47. CCP4: Collaborative Computing Project No. 4 (1994). The CCP4 Suite: Programs for protein crystallography. Acta Crystallog. Sect. D, 50, 760-763.
48. Jones, T. A., Zou, J. Y., Cowan, S. W. & Kjeldgaard, M. (1991). Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallog. Sect. D, 42, 140-149.
49. McRee, D. E. (1999). XtalView/Xfit - A versatile program for manipulating atomic coordinates and electron density. J. Struct. Biol. 125, 156-165.
50. Murshudov, G. N., Vagin, A. A. & Dodson, E. J. (1997). Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallog. Sect. D, 53, 240-255.
51. Brunger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W. et al. (1998). Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallog. Sect. D, 54, 905-921.
52. Piana, S. & Carloni, P. (2000). Conformational flexibility of the catalytic Asp dyad in HIV-1 protease: An ab initio study on the free enzyme. Proteins: Struct. Funct. Genet. 39, 26-36.
53. Connolly, M. L. (1983). Solvent-acessible surfaces of proteins and nucleic acids. Science, 221, 709-713.
54. InsightII 2000, Discover 2.98 (2000). Molecular Simulations Inc., San Diego.
55. King, N. M., Melnick, L., Prabu-Jeyabalan, M., Nalivaika, E. A., Yang, S.-S., Gao, Y. et al. (2002). Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease. Protein Sci. 11, 418-429.